Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

SELL
$0.27 - $0.5 $5,055 - $9,361
-18,723 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$0.37 - $0.54 $6,927 - $10,110
18,723 New
18,723 $9,000
Q4 2021

Feb 17, 2022

SELL
$0.34 - $0.86 $5,112 - $12,932
-15,038 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$0.44 - $0.63 $6,616 - $9,473
15,038 New
15,038 $7,000
Q2 2021

Sep 17, 2021

SELL
$0.48 - $0.72 $30,624 - $45,936
-63,800 Closed
0 $0
Q1 2021

May 19, 2021

SELL
$0.68 - $1.25 $209,942 - $385,923
-308,739 Reduced 82.87%
63,800 $44,000
Q4 2020

Feb 24, 2021

BUY
$0.38 - $0.78 $141,564 - $290,580
372,539 New
372,539 $252,000
Q2 2020

Aug 07, 2020

SELL
$0.41 - $0.73 $123,703 - $220,251
-301,715 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$0.75 - $0.89 $226,286 - $268,526
301,715 New
301,715 $236,000
Q3 2019

Nov 20, 2019

SELL
$0.78 - $1.09 $48,232 - $67,401
-61,836 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$0.98 - $1.64 $42,363 - $70,893
-43,228 Reduced 41.14%
61,836 $72,000
Q1 2019

Apr 12, 2019

BUY
$0.67 - $1.01 $22,804 - $34,376
34,036 Added 47.92%
105,064 $103,000
Q4 2018

Jan 16, 2019

BUY
$0.63 - $1.0 $3,308 - $5,251
5,251 Added 7.98%
71,028 $50,000
Q3 2018

Nov 13, 2018

SELL
$0.88 - $1.1 $77,067 - $96,334
-87,577 Reduced 57.11%
65,777 $66,000
Q1 2018

May 14, 2018

SELL
$0.84 - $1.18 $402,100 - $564,855
-478,691 Reduced 75.74%
153,354 $167,000
Q4 2017

Feb 09, 2018

BUY
$0.68 - $1.0 $199,986 - $294,098
294,098 Added 87.02%
632,045 $543,000
Q3 2017

Nov 15, 2017

BUY
$0.39 - $0.66 $131,799 - $223,045
337,947
337,947 $0

Others Institutions Holding PTN

# of Institutions
1
Shares Held
2.94K
Call Options Held
0
Put Options Held
0

About PALATIN TECHNOLOGIES INC


  • Ticker PTN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,290,480
  • Market Cap $8.83M
  • Description
  • Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...
More about PTN
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.